29 May 2025NewsAmericasRavi Srinivasan, JA Kemp

WATCH: Evergreening (or life cycle management patents—including polymorphs and patents arising from clinical trial data

Ravi Srinivasan of JA Kemp explores strategies for identifying, prosecuting, and defending follow-on patent applications after a therapeutic product enters the public domain. The session at LSPN covers patents based on clinical trial data and polymorphs of small molecule drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
4 June 2026   Justices refuse to place generic drug makers “between a rock and a hard place,” in a landmark ruling clarifying induced patent infringement in pharma.
Americas
3 June 2026   A district court has thrown out one challenge over the vaccine delivery technology, while a separate appeal could affect protections available to government contractors during national emergencies.
Americas
1 June 2026   A district jury has handed a J&J unit a clean sweep in its defence against a rival's heart pump patent claims, delivering a win under the seldom-invoked reverse doctrine of equivalents.